Meridian Bioscience's acquisition of Bioline both provides Meridian a foothold in the PCR market and is expected to help drive future diagnostic development at the company.
Meridian has acquired the reagents maker, adding complementary products to its life science business. The firm also reported an 11 percent decline in Q3 revenues.
The illumigene C. difficile molecular amplification test is Meridian's first molecular diagnostic product.
Meridian Bioscience's Illumigene C. difficile test; Nanosphere's Verigene SP respiratory virus panel; Veredus Laboratories' VereFlu test and VereID Biosystem; and IMDx's 2009 influenza H1N1 assay
The C. difficile test is the first molecular diagnostic product for Meridian. It hopes to market the test later this year.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.